These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
215 related articles for article (PubMed ID: 8548112)
1. Parenteral antiarrhythmic drug therapy in ventricular tachycardia/ventricular fibrillation: evolving role of class III agents--focus on amiodarone. Scheinman MM J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):914-9. PubMed ID: 8548112 [TBL] [Abstract][Full Text] [Related]
2. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent. Singh BN Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328 [TBL] [Abstract][Full Text] [Related]
3. Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Group. Kowey PR; Levine JH; Herre JM; Pacifico A; Lindsay BD; Plumb VJ; Janosik DL; Kopelman HA; Scheinman MM Circulation; 1995 Dec; 92(11):3255-63. PubMed ID: 7586312 [TBL] [Abstract][Full Text] [Related]
4. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Van Herendael H; Dorian P Vasc Health Risk Manag; 2010 Aug; 6():465-72. PubMed ID: 20730062 [TBL] [Abstract][Full Text] [Related]
5. An overview of antiarrhythmic drug management of electrical storm. Kowey PR Can J Cardiol; 1996 Apr; 12 Suppl B():3B-8B; discussion 27B-28B. PubMed ID: 8616726 [TBL] [Abstract][Full Text] [Related]
6. [Anti-arrhythmia agents in the therapy of ventricular arrhythmias in the post-CAST era]. Candinas R; Bauersfeld U Schweiz Med Wochenschr; 1994 Sep; 124(35):1545-9. PubMed ID: 7939521 [TBL] [Abstract][Full Text] [Related]
7. Amiodarone: an emergency medicine perspective. Taylor SE Emerg Med (Fremantle); 2002 Dec; 14(4):422-9. PubMed ID: 12534486 [TBL] [Abstract][Full Text] [Related]
8. Do not consider amiodarone, give it! Comment on antiarrhythmic drugs for shock‑refractory ventricular fibrillation or pulseless ventricular tachycardia. Gibson AE; Jaeschke R Pol Arch Med Wewn; 2016 Oct; 126(10):791-792. PubMed ID: 27872454 [No Abstract] [Full Text] [Related]
9. Contemporary clinical trials in ventricular tachycardia and fibrillation: implications of ESVEM, CASCADE, and CASH for clinical management. Anderson JL J Cardiovasc Electrophysiol; 1995 Oct; 6(10 Pt 2):880-6. PubMed ID: 8548109 [TBL] [Abstract][Full Text] [Related]
10. [Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs]. Haverkamp W; Borggrefe M; Block M; Böcker D; Breithardt G Z Kardiol; 1996; 85 Suppl 6():97-106. PubMed ID: 9064989 [TBL] [Abstract][Full Text] [Related]